Quarterly report pursuant to Section 13 or 15(d)

Fair Value Measurements - Narrative (Details)

v3.24.1.u1
Fair Value Measurements - Narrative (Details)
$ in Millions
1 Months Ended
Jul. 31, 2023
USD ($)
item
Dec. 31, 2023
USD ($)
Jun. 30, 2023
USD ($)
Mar. 31, 2023
USD ($)
Jul. 01, 2022
USD ($)
May 31, 2021
USD ($)
Apr. 06, 2021
USD ($)
Exchange Traded Investment Grade Bond Funds              
Investments, Total     $ 25.0        
Investments, Fair Value Disclosure, Total     23.7        
Asuragen, Inc.              
Contingent consideration     2.0       $ 18.3
Maximum contingent consideration   $ 105.0          
Namocell Inc              
Contingent consideration     $ 1.5   $ 10.6    
Maximum contingent consideration   $ 25.0          
Forward starting swaps | Cash flow hedges | Designated as hedging instruments              
Derivative, Notional Amount       $ 100.0   $ 200.0  
Cross-currency swap | Net investment hedge | Designated as hedging instruments              
Derivative, Notional Amount $ 150.0            
Number of interim settlement dates | item 4            
Notional amount at maturity $ 110.0            
Decrease in notional amount at each interim date $ 10.0